An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumours
Phase of Trial: Phase I/II
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Berzosertib (Primary) ; Carboplatin
- Indications Solid tumours
- Focus Adverse reactions; Pharmacogenomic
- Sponsors Vertex Pharmaceuticals
- 28 Feb 2019 Status changed from recruiting to completed.
- 07 Jun 2016 Results (n=26) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 10 Jan 2016 According to Vertex media release, preliminary data expected at the medical meetings in 2016.